Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus BCG versus BCG alone in high-risk non-muscle invasive bladder cancer
NL-OMON58844Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of durvalumab in non-muscle-invasive bladder cancer (NMIBC) and transitional cell carcinoma (TCC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Disease-free survival. Started Dec 2018; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON58844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58844.